Dr. Zhiming Li earned his PhD (eight-year program) from Peking University in 2018. From 2018 to 2024, he conducted postdoctoral research at Columbia University. In January 2025, he joined the National Key Laboratory of Biotherapy at Sichuan University and the West China School of Public Health/West China Fourth Hospital (dual appointment) as a full-time Principal Investigator and doctoral supervisor. His long-term research focuses on "epigenetic regulation of genome stability," exploring the role of epigenetic dysregulation in the progression of human diseases and its potential applications.